6 Nov 2017 BAARN (Boston Area Antimicrobial Resistance Network) + 7-8 Nov BARDA Industry Days

Dear All:

Early November will be busy! First, BAARN is having their annual meeting in the Boston area on 6 Nov. See below a note from Michael Gilmore with details. If you are in Boston on that day, I highly recommend this meeting as a superb scientific event & networking opportunity.

Second, you can then go from BAARN to BARDA’s Industry Days in DC on 7-8 Nov. Here’s the registration link for more details. This is an opportunity to learn about BARDA’s strategic goals for FY18 and beyond while networking with members of ASPR, BARDA, AMCG and other government and industry stakeholders. If you are consider US government funding, this is a great way to learn about working with BARDA and its USG partners.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Mike writes: Tickets for the 2017 annual Boston Area Antibiotic Resistance Network meeting are now available at this link. The event will be on 6 Nov 2017 at the American Academy of Arts and Science’s Norton Woods Conference Center, adjacent to the Harvard campus (200 Beacon St., Somverville MA). The auditorium is limited to 200 attendees, so register early and notify friends and associates you know to be interested.

In response to feedback from last year, there will be more opportunity for 1-on-1 networking throughout the day. There will also be a rapid fire session for new biotechs to introduce their new efforts to the community.

The program:
8:00 – 8:30 Registration
8:30  Welcome

8:35 Session I: Advances in new therapeutics
10:15 – 11:00 Networking over coffee

11:00  Session II: Advances in alternatives to antibiotics for managing host microbe interactions
12:15 Lunch and more networking

2:00  Session III: Advances in Diagnostics
3:40 – 4:00 Short Break

4:00  Federal resources that can help (NIH Research Resources & Translational. Research DMID)
4:30  Short poster pitches from select treatment or diagnostic biotech startups

5:15 Networking and posters
7:00 Adjourn

​——————————
Upcoming meetings of interest to the AMR community:

Share

Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top